Substituted oxadiazolidinediones ALS PAI-1 inhibitors

Details for Australian Patent Application No. 2004275808 (hide)

Owner Wyeth

Inventors Kincaid, Scott Lee; Gopalsamy, Ariamala

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2004275808

PCT Pub. Number WO2005/030203

Priority 60/505,782 25.09.03 US; 10/947,810 23.09.04 US

Filing date 24 September 2004

Wipo publication date 7 April 2005

International Classifications

C07D 271/07 (2006.01) Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms

C07D 413/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 413/06 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

27 April 2006 PCT application entered the National Phase

  PCT publication WO2005/030203 Priority application(s): WO2005/030203

22 April 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004275809-Nitrosated glutamic acid compounds, compositions and methods of use

2004275807-4-(1-benzofuran-3-yl-methylideneamino xy.propoxy))-benzoic acid derivatives and related compounds as PAI-1 inhibitors for the treatment of impairment of the fibrinolytic system and of thrombosis